The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

The present invention provides an easy and efficient method for manufacturing a feed containing a salmon growth hormone with biological activity. The method for manufacturing a feed containing a salmon growth hormone of the present invention includes a step of heating a pulverized salmon head at 30 C. or higher and 90 C. or lower. A feed containing a salmon growth hormone of the present invention is obtained by the above manufacturing method. A liquid containing a salmon growth hormone of the present invention is obtained by heating a pulverized salmon head at 30 C. or higher and 90 C. or lower and separating a solid component from a fluid component of the heated salmon head.

The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.

The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.

The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.

The present invention is directed to methods for increasing the quality of crop plant silage that are consumed by milk and meat-producing animals. The methods involve the following steps: 1) treating plants with a gibberellin; 2) producing silage from the plants treated according to step 1); and 3) feeding silage produced according to step 2) to milk and/or meat-producing animals. Applicants' methods result in higher quality meat from the meat-producing animals and increased milk from the milk-producing animals.

The present invention is directed to methods for increasing the quality of crop plant silage that are consumed by milk and meat-producing animals. The methods involve the following steps: 1) treating plants with a gibberellin; 2) producing silage from the plants treated according to step 1); and 3) feeding silage produced according to step 2) to milk and/or meat-producing animals. Applicants' methods result in higher quality meat from the meat-producing animals and increased milk from the milk-producing animals.

Anguilliformes breeding water contains a thyroid hormone such as thyroxine, and a method for rearing anguilliformes includes a step for administering a thyroid hormone such as thyroxine, wherein the amount of the thyroid hormone to be administered changes as the anguilliforme fingerling changes from a transformation start phase (stage 1) to a transformation final phase (stage 2), and the amount of the thyroid hormone to be administered in the transformation final phase (stage 2) is less than the amount of the thyroid hormone to be administered in the transformation start phase (stage 1).